Siemens-backed cancer therapy developer ViewRay has raised $26.7m in equity and gone public through a reverse merger with a shell company.

SutroVax, a Sutro Biopharma spin-out that also counts Johnson & Johnson as an investor, will use the series A capital to further develop its biopharmaceutical vaccines.

The series B funding will help KalVista, a spin-out of Vantia Therapeutics, to advance treatments for diabetes and blood disease to clinical trials.

The Novartis-backed eye disease treatment developer, which filed to go public earlier this month, has now raised almost $78m from two equity rounds.

Bima's existing investors, including Millicom and Digicel, backed the insurance platform's $38.4m series C round, taking its overall funding to more than $67m.

Ride sharing service Ola has participated in the mobile payments processing service's series C round, which was led by hedge fund Falcon Edge.

The LED lighting-based sensor maker secured the series C capital from Cisco, Acuity Brands, General Electric and Simon Property Group.

SoftBank has led a series B round for advertising and data analytics company Cinarra, which follows a $4.5m Cisco-backed series A round in 2013.

McKesson and Independence Health provided the capital for healthcare marketplace Accolade, which previously received funding from investors including Comcast.